Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

228.34 +1.03 (+0.45%)
Streaming Delayed Price Updated: 11:09 AM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories Intl

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Wells Fargo Maintains Overweight Rating for Charles River: Here's What You Need To Know
Wells Fargo has decided to maintain its Overweight rating of Charles River (NYSE:CRL) and lower its price target from $390.00 to $325.00. Shares of Charles River are trading down 7.96% over the last 24... 
Via Benzinga
What 6 Analyst Ratings Have To Say About Charles River
Analysts have provided the following ratings for Charles River (NYSE:CRL) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
Recap: Charles River Q4 Earnings
  Charles River (NYSE:CRL) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 16, 2022
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million. 
Via Benzinga
10 Biggest Price Target Changes For Monday
Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading. 
Via Benzinga
Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Publishes 2021 Corporate Citizenship Report
From Charles River Laboratories International, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2022
Upgrades 
Via Benzinga
Charles River Buys Contract Vivarium Research Services Firm In $295M Deal
Charles River Laboratories International Inc (NYSE: CRL) has acquired Explora BioLabs Holdings Inc, a provider of contract vivarium research services,  
Via Benzinga
Charles River Laboratories Acquires Explora BioLabs
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories to Appoint Flavia H. Pease as Chief Financial Officer
From Charles River Laboratories International, Inc.
Via Business Wire
Markets Fall Amid Rising Oil Prices
U.S. indices finished lower Wednesday as investors continue to weigh the Federal Reserve tapering outlook, inflation concerns and the Russia-Ukraine war. Oil prices have also... 
Via Benzinga
Inflation Beneficiary ETFs in Focus as Prices Soar
Many experts predicted that inflation would cool off in spring as supply chains improve after pandemic-driven disruptions. It now appears that higher inflation could persist for longer. 
Via Talk Markets
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature. 
Via InvestorPlace
Charles River Earnings Perspective: Return On Invested Capital
According to Benzinga Pro, during Q4, Charles River (NYSE:CRL) earned $139.83 million, a 32.97% increase from the preceding quarter. Charles River also posted a total of $905.05 million in sales, a... 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Cowen & Co. raised Yum! Brands, Inc. (NYSE: YUM) price target from $134 to $143. Yum! Brands shares fell 0.3% to $123.00 in pre-market trading. Keybanc cut the price target... 
Via Benzinga
Charles River's Q4 Earnings Beats Street Expectation, Reaffirms FY22 Outlook
Charles River Laboratories International Inc's (NYSE: CRL)  
Via Benzinga
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Announces Wind Contract with Repsol for European Operations
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Expands Strategic Partnership With SAMDI Tech
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Access to AI-Enabled Drug Discovery Solutions
From Charles River Laboratories International, Inc.
Via Business Wire
The Best and Worst of Q4 Earnings
Earnings season begins this week as corporations report their Q4 results and wrap up fiscal year 2021. 
Via Talk Markets
Charles River Laboratories Announces Chief Financial Officer Retirement and Transition Plan
From Charles River Laboratories International, Inc.
Via Business Wire
Will Chart Analysts Notice Bad Omen on Charles River's Chart
If history is any guide, there may be trouble ahead for shares of Charles River (NYSE:CRL). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
Virpax Posts Toxicology, Pharmacokinetic Data For Pain Med Epoladerm
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) reported results following toxicology and pharmacokinetic study of Epoladerm to manage pain associated with... 
Via Benzinga
Charles River Laboratories to Participate in Upcoming Investor Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Promotes Birgit Girshick to Chief Operating Officer
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.